Investment analysts at Barclays PLC initiated coverage on shares of Editas Medicine Inc (NASDAQ:EDIT) in a research note issued on Wednesday, Marketbeat Ratings reports. The firm set an “overweight” rating and a $28.00 price target on the stock. Barclays PLC’s price objective indicates a potential upside of 39.37% from the company’s current price.

EDIT has been the subject of several other research reports. SunTrust Banks, Inc. began coverage on shares of Editas Medicine in a research report on Thursday, July 13th. They set a “hold” rating and a $17.00 price target for the company. Oppenheimer Holdings, Inc. reiterated a “market perform” rating on shares of Editas Medicine in a research note on Tuesday, July 18th. Cann reaffirmed a “hold” rating on shares of Editas Medicine in a research note on Thursday, August 10th. Zacks Investment Research raised shares of Editas Medicine from a “hold” rating to a “buy” rating and set a $19.00 price objective for the company in a research note on Wednesday, July 12th. Finally, J P Morgan Chase & Co set a $27.00 price objective on shares of Editas Medicine and gave the company a “hold” rating in a research note on Wednesday, August 9th. Five equities research analysts have rated the stock with a hold rating, four have issued a buy rating and one has given a strong buy rating to the stock. The stock has an average rating of “Buy” and a consensus target price of $25.52.

Shares of Editas Medicine (EDIT) traded down 0.54% on Wednesday, hitting $20.09. The stock had a trading volume of 973,796 shares. The firm’s 50-day moving average price is $18.77 and its 200 day moving average price is $19.11. The firm’s market cap is $822.20 million. Editas Medicine has a 12 month low of $12.43 and a 12 month high of $29.20.

Editas Medicine (NASDAQ:EDIT) last released its quarterly earnings results on Wednesday, August 9th. The company reported ($0.65) earnings per share for the quarter, missing the consensus estimate of ($0.64) by $0.01. Editas Medicine had a negative return on equity of 54.18% and a negative net margin of 853.70%. The company had revenue of $3.10 million for the quarter, compared to analyst estimates of $2.20 million. During the same quarter last year, the company earned ($0.54) EPS. The firm’s revenue for the quarter was down 8.8% on a year-over-year basis. Analysts anticipate that Editas Medicine will post ($2.88) EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Editas Medicine Inc (EDIT) Coverage Initiated by Analysts at Barclays PLC” was first reported by American Banking News and is the sole property of of American Banking News. If you are viewing this report on another site, it was illegally copied and reposted in violation of United States and international copyright and trademark law. The legal version of this report can be read at https://www.americanbankingnews.com/2017/09/10/editas-medicine-inc-edit-coverage-initiated-by-analysts-at-barclays-plc.html.

In related news, CEO Katrine Bosley sold 10,000 shares of the company’s stock in a transaction dated Friday, September 1st. The shares were sold at an average price of $20.42, for a total transaction of $204,200.00. Following the completion of the sale, the chief executive officer now owns 1,414,629 shares of the company’s stock, valued at approximately $28,886,724.18. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In the last ninety days, insiders have sold 43,332 shares of company stock valued at $876,673.

A number of hedge funds and other institutional investors have recently made changes to their positions in EDIT. Wells Fargo & Company MN grew its stake in Editas Medicine by 31.0% during the 1st quarter. Wells Fargo & Company MN now owns 64,980 shares of the company’s stock valued at $1,451,000 after acquiring an additional 15,361 shares in the last quarter. Henderson Group PLC purchased a new stake in Editas Medicine during the 1st quarter valued at about $1,116,000. Bank of New York Mellon Corp grew its stake in Editas Medicine by 53.3% during the 1st quarter. Bank of New York Mellon Corp now owns 63,490 shares of the company’s stock valued at $1,418,000 after acquiring an additional 22,061 shares in the last quarter. Swiss National Bank grew its stake in Editas Medicine by 33.2% during the 1st quarter. Swiss National Bank now owns 40,100 shares of the company’s stock valued at $895,000 after acquiring an additional 10,000 shares in the last quarter. Finally, TD Asset Management Inc. grew its stake in Editas Medicine by 9.0% during the 1st quarter. TD Asset Management Inc. now owns 33,770 shares of the company’s stock valued at $754,000 after acquiring an additional 2,800 shares in the last quarter. 70.17% of the stock is owned by institutional investors.

Editas Medicine Company Profile

Editas Medicine, Inc is a genome editing company. It is engaged in treating patients with genetically defined diseases by correcting their disease-causing genes. It operates through developing and commercializing genome editing technology segment. It is developing a genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR) technology.

Analyst Recommendations for Editas Medicine (NASDAQ:EDIT)

Receive News & Ratings for Editas Medicine Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Editas Medicine Inc and related companies with MarketBeat.com's FREE daily email newsletter.